Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity

C H Köhne; P Thuss-Patience; M Friedrich; P T Daniel; A Kretzschmar; T Benter; B Bauer; R Dietz; B Dörken

doi:10.1038/bjc.1998.160

Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity

Br J Cancer. 1998 Mar;77(6):973-7. doi: 10.1038/bjc.1998.160.

Authors

C H Köhne¹, P Thuss-Patience, M Friedrich, P T Daniel, A Kretzschmar, T Benter, B Bauer, R Dietz, B Dörken

Affiliation

¹ Department of Haematology/Oncology and Tumor Immunology Robert-Rössle-Klinik, Virchow-Klinikum, Medizinische Fakultät Charite der Humboldt-Universität zu Berlin, Germany.

Abstract

Two patients with proven 5-fluorouracil (5-FU)-associated cardiotoxicity were treated with the specific thymidylate synthase inhibitor raltitrexed safely, without evidence of cardiotoxicity. Raltitrexed might be an alternative for patients with advanced colorectal cancer and 5-FU-associated cardiotoxicity. 5-FU cardiotoxicity is not due to the antineoplastic mechanisms via thymidilate synthase.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / secondary*
Antimetabolites, Antineoplastic / therapeutic use*
Electrocardiography / drug effects*
Female
Fluorouracil / adverse effects*
Heart / drug effects*
Humans
Liver Neoplasms / drug therapy
Liver Neoplasms / secondary*
Lung Neoplasms / drug therapy
Lung Neoplasms / secondary*
Male
Middle Aged
Quinazolines / therapeutic use*
Sigmoid Neoplasms / drug therapy*
Sigmoid Neoplasms / pathology
Thiophenes / therapeutic use*
Thymidylate Synthase / antagonists & inhibitors

Substances

Antimetabolites, Antineoplastic
Quinazolines
Thiophenes
Thymidylate Synthase
raltitrexed
Fluorouracil